Dr. Lingvay is a clinical investigator in the filed of diabetse, obesity, and associated metabolic complications. She leads an active clinical research program in the Division of Endocrinology at Univeristy of Texas Southwestern Medical Center in Dallas. Her research interests span from pathophysiology to finding new treatment options to improve the lives of patients with such conditions. Dr. Lingvay graduated from medical school among the top 5% of her class. She completed the Internal Medicine Residency at Texas Tech University in 2002, and Endocrinology, Diabetes and Metabolism Fellowship at University of Texas Southwestern Medical Center in 2005. Dr. Lingvay was selected to participate in the first class of the Clinical Research Scholars Program at UT Southwestern which she completed in 2008. In 2007 she received a National Institute of Health Career Development Award to study the role of pancreatic triglyceride accumulation in beta-cell failure and type 2 diabetes and to further develop her career as a clinical investigator. Dr. Lingvay also received the Master in Public Health degree from University of Texas School of Public Health in Houston in 2006. She has published her work in many renouned journals like JAMA New Engladn Journal of Medicine, Lancet, Circulation, and Diabetes Care. She has contributed to many textbooks in the field of diabetes and is on the editorial board of several journals. Dr. Lingvay has been invited to present lectures to her peers all over the world. She is an active member of American Diabetes Association, and has served on the scientific sessions organizing committee from 2016 to 2019.


Medical School
Carol Davila University of Medicine & Pharmacy (1998)
Texas Tech University Health Sciences Center (2002), Internal Medicine
UT Southwestern Medical Center (2005), Endocrinology & Metabolism
Graduate School
University of Texas Health Science Center at Houston (2006), Public Health
Graduate School
UT Southwestern Medical Center (2008), Clinical Research

Research Interest

  • Metabolic Syndrome
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)
  • Obesity
  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus


Featured Publications LegendFeatured Publications

Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Vanderheiden A, Harrison L, Warshauer J, Li X, Adams-Huet B, Lingvay I JAMA Intern Med 2016 Jun
Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI.
Yokoo T, Clark HR, Pedrosa I, Yuan Q, Dimitrov I, Zhang Y, Lingvay I, Beg MS, Bobulescu IA J Magn Reson Imaging 2016 Mar
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I, Manghi FP, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB JAMA 2016 Mar 315 9 898-907
Mechanisms of Action of Liraglutide in Patients with Type 2 Diabetes Treated with High Dose Insulin.
Vanderheiden A, Harrison LB, Warshauer JT, Adams-Huet B, Li X, Yuan Q, Hulsey K, Dimitrov I, Yokoo T, Jaster AW, Pinho DF, Pedrosa I, Lenkinski RE, Pop LM, Lingvay I J. Clin. Endocrinol. Metab. 2016 Feb jc20153906
First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report.
Dao BD, Lingvay I, Sailors J, Landay M, Shapiro G J Investig Med High Impact Case Rep 2015 Jul-Sep 3 3 2324709615603723
Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges.
Gore MO, McGuire DK, Lingvay I, Rosenstock J Curr Cardiol Rep 2015 Jul 17 7 607
State of the Art: Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Anti-hyperglycemic Medications.
Alvarez CA, Lingvay I, Vuylsteke V, Koffarnus RL, McGuire DK Clin. Pharmacol. Ther. 2015 May
Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome.
Warshauer JT, Lopez X, Gordillo R, Hicks J, Holland WL, Anuwe E, Blankfard MB, Scherer PE, Lingvay I Diabetes Metab. Res. Rev. 2015 May
Random Blood Glucose: A Robust Risk Factor For Type 2 Diabetes.
Bowen ME, Xuan L, Lingvay I, Halm EA J. Clin. Endocrinol. Metab. 2015 Feb jc20144116
Comparative Evaluation of Two Venous Sampling Techniques for the Assessment of Pancreatic Insulin and Zinc Release upon Glucose Challenge.
Pillai AK, Silvers W, Christensen P, Riegel M, Adams-Huet B, Lingvay I, Sun X, Öz OK J Diabetes Res 2015 2015 789359


Featured Books Legend Featured Books

Secondary Forms of Diabetes Mellitus. In American College of Physicians- Medicine

Lingvay I, Raskin P (2006). American College of Physicians

Non-insulin Pharmacological Therapies. In Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management

Lingvay I, Rhee C, Raskin P (2006).

Honors & Awards

  • Jean W. Wilson Award for Scientific Mentorship
  • Jean W. Wilson Award for Scientific Mentorship

Professional Associations/Affiliations

  • American Diabetes Association
  • American Federation for Medical Research
  • European Association for the Study of Diabetes
  • The Endocrine Society